10.24

1.88% -0.1101

Nuvectis Pharma Inc (NVCT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$10.35

Offen:

$10.5

24-Stunden-Volumen:

97,419

Relative Volume:

1.33

Marktkapitalisierung:

$270.30M

Einnahmen:

Nettoeinkommen (Verlust:

$-28.87M

KGV:

-7.975

EPS:

-1.284

Netto-Cashflow:

$-16.01M

1W Leistung:

-1.41%

1M Leistung:

+14.10%

6M Leistung:

+67.57%

1J Leistung:

+3.31%

1-Tages-Spanne:

$10.00

$10.73

1-Wochen-Bereich:

$10.00

$11.40

52-Wochen-Spanne:

$5.55

$13.34

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Firmenname

Nuvectis Pharma Inc

Sektor

Healthcare (1110)

Branche

Biotechnology (618)

Telefon

360-837-7232

Adresse

1 BRIDGE PLAZA, SUITE 275, FORT LEE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-05

Neueste SEC-Einreichungen

NVCT's Discussions on Twitter

Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCT Nuvectis Pharma Inc	10.19	274.54M	0	-28.87M	-16.01M	-1.284
VRTX Vertex Pharmaceuticals Inc	436.73	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.59	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.19	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.70	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.32	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-02	Eingeleitet	Maxim Group	Buy
2025-03-17	Eingeleitet	Laidlaw	Buy
2022-07-13	Eingeleitet	Ladenburg Thalmann	Buy

Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten

May 25, 2026

Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN

May 25, 2026

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com

May 25, 2026

May 21, 2026

Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21Low Volatility Picks - Newser

May 21, 2026

May 19, 2026

Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily

May 19, 2026

May 15, 2026

NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill

May 15, 2026

May 14, 2026

Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union

May 14, 2026

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times

May 14, 2026

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record

May 14, 2026

May 13, 2026

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN

May 11, 2026

May 10, 2026

Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN

May 10, 2026

May 08, 2026

The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily

May 08, 2026

What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com

May 08, 2026

May 07, 2026

Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail

May 07, 2026

May 06, 2026

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st

May 06, 2026

May 05, 2026

Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 05, 2026

Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo

May 05, 2026

Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView

May 05, 2026

Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan

May 05, 2026

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov

May 05, 2026

Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2026

Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union

May 05, 2026

Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan

May 05, 2026

Nuvectis Pharma reports Q1 2026 loss of $6.1M, advances NXP900 cancer drug trials with data expected in summer. - Pluang

May 05, 2026

May 04, 2026

Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance

May 04, 2026

May 03, 2026

NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com

May 03, 2026

May 01, 2026

Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 01, 2026

Apr 30, 2026

NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill

Apr 30, 2026

Apr 29, 2026

Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser

Apr 29, 2026

Apr 28, 2026

Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 27, 2026

Nuvectis Pharma (NASDAQ: NVCT) details 2026 annual meeting and executive pay - Stock Titan

Apr 27, 2026

Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily

Apr 27, 2026

NVCT (Nuvectis Pharma) posts slight Q4 2025 EPS miss, yet shares edge higher on positive investor sentiment.Convertible Notes - Newser

Apr 27, 2026

Apr 16, 2026

Technical Reactions to NVCT Trends in Macro Strategies - Stock Traders Daily

Apr 16, 2026

Apr 13, 2026